Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib

    loading  Checking for direct PDF access through Ovid

Abstract

Vemurafenib is an inhibitor of BRAF and is used to treat patients with metastatic melanoma who carry a V600E BRAF mutation. Recently, four patients have been described in the literature who developed a neutrophilic panniculitis following treatment with a BRAF inhibitor. We present an additional case and review the clinical findings of the cases reported to date.

Related Topics

    loading  Loading Related Articles